Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPB-101 in Advanced Solid Tumors
NCT05869240Phase 2Unknown
- Sponsor
- Betta Pharmaceuticals
- Start
- May 2023
- Primary completion
- Aug 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of BPB-101 in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), esophageal cancer, colorectal cancer (CRC), endometrial cancer (EC), sponsored by Betta Pharmaceuticals. Status: unknown.
02
Drugs
BPB-101
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)esophageal cancercolorectal cancer (CRC)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT05869240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05869240.